Menu Search
Equities

Rhythm Biosciences Ltd

RHY:ASX

Rhythm Biosciences Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (AUD)0.061
  • Today's Change-0.001 / -1.61%
  • Shares traded101.72k
  • 1 Year change-79.23%
  • Beta2.3197
Data delayed at least 20 minutes, as of Sep 20 2024 04:24 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in AUDIncome statement in AUDView more

Year on year Rhythm Biosciences Ltd had revenues fall -77.10% from 228.27k to 52.28k, though the company grew net income from a loss of 8.22m to a smaller loss of 6.86m.
Gross margin-4,946.29%
Net profit margin-13,115.47%
Operating margin-16,342.31%
Return on assets-148.83%
Return on equity-203.42%
Return on investment-199.13%
More ▼

Cash flow in AUDView more

In 2024, cash reserves at Rhythm Biosciences Ltd fell by 3.41m. Cash Flow from Financing totalled 2.80m or 5,364.90% of revenues. In addition the company used 6.14m for operations while cash used for investing totalled 82.28k.
Cash flow per share-0.0292
Price/Cash flow per share--
Book value per share0.0035
Tangible book value per share0.0021
More ▼

Balance sheet in AUDView more

Rhythm Biosciences Ltd appears to have a strong balance sheet with enough cash in the capital structure to pay down 100% of the liabilities.
Current ratio1.58
Quick ratio1.58
Total debt/total equity0.1889
Total debt/total capital0.1589
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.